Advances in Biomarker Research in Parkinson’s Disease

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease, and the numbers are projected to double in the next two decades with the increase in the aging population. An important focus of current research is to develop interventions to slow the progression of the disease. However, prerequisites to it include the development of reliable biomarkers for early diagnosis which would identify at-risk groups and disease progression. In this review, we present updated evidence of already known clinical biomarkers (such as hyposmia and rapid eye movement (REM) sleep behavior disorder (RBD)) and neuroimaging biomarkers, as well as newer possible markers in the blood, CSF, and other tissues. While several promising candidates and methods to assess these biomarkers are on the horizon, it is becoming increasingly clear that no one candidate will clearly fulfill all the roles as a single biomarker. A multimodal and combinatorial approach to develop a battery of biomarkers will likely be necessary in the future.

Original languageEnglish (US)
Article number7
Pages (from-to)1-8
Number of pages8
JournalCurrent Neurology and Neuroscience Reports
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Parkinson Disease
Biomarkers
Research
Disease Progression
REM Sleep Behavior Disorder
Neuroimaging
Neurodegenerative Diseases
Early Diagnosis
Population

Keywords

  • Biomarkers
  • Dopaminergic imaging
  • Parkinson’s disease
  • Transcranial ultrasound
  • α-synuclein

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Advances in Biomarker Research in Parkinson’s Disease. / Mehta, Shyamal; Adler, Charles Howard.

In: Current Neurology and Neuroscience Reports, Vol. 16, No. 1, 7, 01.01.2016, p. 1-8.

Research output: Contribution to journalArticle

@article{0948a189376f4b929b104d2ce9fb4e00,
title = "Advances in Biomarker Research in Parkinson’s Disease",
abstract = "Parkinson’s disease (PD) is the second most common neurodegenerative disease, and the numbers are projected to double in the next two decades with the increase in the aging population. An important focus of current research is to develop interventions to slow the progression of the disease. However, prerequisites to it include the development of reliable biomarkers for early diagnosis which would identify at-risk groups and disease progression. In this review, we present updated evidence of already known clinical biomarkers (such as hyposmia and rapid eye movement (REM) sleep behavior disorder (RBD)) and neuroimaging biomarkers, as well as newer possible markers in the blood, CSF, and other tissues. While several promising candidates and methods to assess these biomarkers are on the horizon, it is becoming increasingly clear that no one candidate will clearly fulfill all the roles as a single biomarker. A multimodal and combinatorial approach to develop a battery of biomarkers will likely be necessary in the future.",
keywords = "Biomarkers, Dopaminergic imaging, Parkinson’s disease, Transcranial ultrasound, α-synuclein",
author = "Shyamal Mehta and Adler, {Charles Howard}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s11910-015-0607-4",
language = "English (US)",
volume = "16",
pages = "1--8",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Advances in Biomarker Research in Parkinson’s Disease

AU - Mehta, Shyamal

AU - Adler, Charles Howard

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Parkinson’s disease (PD) is the second most common neurodegenerative disease, and the numbers are projected to double in the next two decades with the increase in the aging population. An important focus of current research is to develop interventions to slow the progression of the disease. However, prerequisites to it include the development of reliable biomarkers for early diagnosis which would identify at-risk groups and disease progression. In this review, we present updated evidence of already known clinical biomarkers (such as hyposmia and rapid eye movement (REM) sleep behavior disorder (RBD)) and neuroimaging biomarkers, as well as newer possible markers in the blood, CSF, and other tissues. While several promising candidates and methods to assess these biomarkers are on the horizon, it is becoming increasingly clear that no one candidate will clearly fulfill all the roles as a single biomarker. A multimodal and combinatorial approach to develop a battery of biomarkers will likely be necessary in the future.

AB - Parkinson’s disease (PD) is the second most common neurodegenerative disease, and the numbers are projected to double in the next two decades with the increase in the aging population. An important focus of current research is to develop interventions to slow the progression of the disease. However, prerequisites to it include the development of reliable biomarkers for early diagnosis which would identify at-risk groups and disease progression. In this review, we present updated evidence of already known clinical biomarkers (such as hyposmia and rapid eye movement (REM) sleep behavior disorder (RBD)) and neuroimaging biomarkers, as well as newer possible markers in the blood, CSF, and other tissues. While several promising candidates and methods to assess these biomarkers are on the horizon, it is becoming increasingly clear that no one candidate will clearly fulfill all the roles as a single biomarker. A multimodal and combinatorial approach to develop a battery of biomarkers will likely be necessary in the future.

KW - Biomarkers

KW - Dopaminergic imaging

KW - Parkinson’s disease

KW - Transcranial ultrasound

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=84952039556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952039556&partnerID=8YFLogxK

U2 - 10.1007/s11910-015-0607-4

DO - 10.1007/s11910-015-0607-4

M3 - Article

VL - 16

SP - 1

EP - 8

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 1

M1 - 7

ER -